聚腺苷二磷酸核糖聚合酶抑制劑rucaparib
發(fā)布時(shí)間：2019-08-14 21:01
【摘要】：近年來(lái)乳腺癌、卵巢癌、胰腺癌等實(shí)體瘤的發(fā)病率逐年增加,臨床上還缺乏有效的治療藥物。作為第1個(gè)用于人類癌癥療法的聚腺苷二磷酸核糖聚合酶(PARP)抑制劑,臨床前研究表明rucaparib可明顯抑制乳腺癌、卵巢癌等實(shí)體瘤。臨床研究顯示rucaparib具有良好的安全性和有效性。主要從rucaparib的藥物概況、相關(guān)背景、合成路線、臨床前研究和臨床研究方面進(jìn)行介紹。
[Abstract]:In recent years, the incidence of breast cancer, ovarian cancer, pancreatic cancer and other solid tumors has increased year by year, and there is still a lack of effective drugs in clinic. As the first polyadenosine diphosphate ribose polymerase (PARP) inhibitor for human cancer therapy, preclinical studies have shown that rucaparib can significantly inhibit breast cancer, ovarian cancer and other solid tumors. Clinical studies have shown that rucaparib has good safety and effectiveness. This paper mainly introduces the drug situation, related background, synthetic route, preclinical research and clinical research of rucaparib.
【作者單位】： 天津藥物研究院;
【分類號(hào)】：R979.1
本文編號(hào)：2526800
[Abstract]:In recent years, the incidence of breast cancer, ovarian cancer, pancreatic cancer and other solid tumors has increased year by year, and there is still a lack of effective drugs in clinic. As the first polyadenosine diphosphate ribose polymerase (PARP) inhibitor for human cancer therapy, preclinical studies have shown that rucaparib can significantly inhibit breast cancer, ovarian cancer and other solid tumors. Clinical studies have shown that rucaparib has good safety and effectiveness. This paper mainly introduces the drug situation, related background, synthetic route, preclinical research and clinical research of rucaparib.
【作者單位】： 天津藥物研究院;
【分類號(hào)】：R979.1
【相似文獻(xiàn)】
相關(guān)期刊論文 前1條
1 耿元碩;胡珀;王欣;劉超;李志裕;;聚腺苷二磷酸核糖聚合酶抑制劑Rucaparib的合成研究[J];精細(xì)化工中間體;2012年05期
，本文編號(hào)：2526800
本文鏈接：http://sikaile.net/yixuelunwen/yiyaoxuelunwen/2526800.html
最近更新
教材專著
